Today, antibodies directed against programmed cell death protein 1 (anti‐PD‐1) are the first‐choice treatment option in patients with metastatic or locally advanced cSCC [13, 14, 15]. This evidence concerns the gene PDCD1 and skin squamous cell carcinoma.